A growing number of drugs and vaccines have been discovered using AI, but questions remain about the success of these molecules in clinical trials. To address these questions, the authors conducted a first analysis of the clinical pipelines of AI-native biotech companies.
We thank Ilyass El-Mansouri and Gaetan Rensonnet for their contributions to this article.